

Ebba Brakenhielm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8798175/publications.pdf>

Version: 2024-02-01

42
papers

4,787
citations

218677

26
h-index

302126

39
g-index

44
all docs

44
docs citations

44
times ranked

6398
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation and impact of cardiac lymphangiogenesis in pressure-overload-induced heart failure. <i>Cardiovascular Research</i> , 2023, 119, 492-505.	3.8	10
2	Cardiac lymphatics. <i>Current Opinion in Hematology</i> , 2022, Publish Ahead of Print, .	2.5	0
3	Theme and main topic index. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 208-213.	1.9	0
4	Transient heart rate reduction improves acute decompensated heart failure-induced left ventricular and coronary dysfunction. <i>ESC Heart Failure</i> , 2021, 8, 1085-1095.	3.1	6
5	Lymphatics in the broken heart. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	1
6	Role of Cardiac Lymphatics in Myocardial Edema and Fibrosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 735-744.	2.8	45
7	Lymphatic and Immune Cell Cross-Talk Regulates Cardiac Recovery After Experimental Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1722-1737.	2.4	65
8	Assessing functional status of cardiac lymphatics: From macroscopic imaging to molecular profiling. <i>Trends in Cardiovascular Medicine</i> , 2020, 31, 333-338.	4.9	6
9	Microvascular and lymphatic dysfunction in HFrEF and its associated comorbidities. <i>Basic Research in Cardiology</i> , 2020, 115, 39.	5.9	77
10	Cardiac lymphatics in health and disease. <i>Nature Reviews Cardiology</i> , 2019, 16, 56-68.	13.7	118
11	Therapeutic vascular growth in the heart. <i>Vascular Biology (Bristol, England)</i> , 2019, 1, H9-H15.	3.2	1
12	Does anti-VEGF bevacizumab improve survival in experimental sepsis?. <i>Critical Care</i> , 2017, 21, 163.	5.8	12
13	Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction. <i>Circulation</i> , 2016, 133, 1484-1497.	1.6	245
14	Role of M2-like macrophage recruitment during angiogenic growth factor therapy. <i>Angiogenesis</i> , 2015, 18, 191-200.	7.2	41
15	Angiostatic Effects of NK Cell-Derived IFN- γ Counteracted by Tumour Cell Bcl-2 Expression. <i>Scandinavian Journal of Immunology</i> , 2014, 79, 90-97.	2.7	5
16	Role of Toll-like Receptors 2 and 4 in Mediating Endothelial Dysfunction and Arterial Remodeling in Primary Arterial Antiphospholipid Syndrome. <i>Arthritis and Rheumatology</i> , 2014, 66, 3210-3220.	5.6	45
17	Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice. <i>FASEB Journal</i> , 2014, 28, 3351-3361.	0.5	46
18	Leptin, Adiponectin, and Other Adipokines in Regulation of Adipose Tissue Angiogenesis. , 2013, , 187-228.		0

#	ARTICLE	IF	CITATIONS
19	Heart Rate Reduction Induced by the If Current Inhibitor Ivabradine Improves Diastolic Function and Attenuates Cardiac Tissue Hypoxia. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 59, 260-267.	1.9	44
20	Progenitor Cell Mobilizing Treatments Prevent Experimental Transplant Arteriosclerosis. <i>Journal of Surgical Research</i> , 2012, 176, 657-665.	1.6	9
21	Arteriogenic Therapy by Intramyocardial Sustained Delivery of a Novel Growth Factor Combination Prevents Chronic Heart Failure. <i>Circulation</i> , 2011, 124, 1059-1069.	1.6	84
22	<i>In Vitro</i> and <i>Ex Vivo</i> Evaluation of Smart Infra-Red Fluorescent Caspase-3 Probes for Molecular Imaging of Cardiovascular Apoptosis. <i>International Journal of Molecular Imaging</i> , 2011, 2011, 1-13.	1.3	3
23	Adipose angiogenesis: quantitative methods to study microvessel growth, regression and remodeling in vivo. <i>Nature Protocols</i> , 2010, 5, 912-920.	12.0	66
24	H031 Short-term heart rate reduction induced by ivabradine administered to rats with well-established heart failure improves cardiac function, augments neo-angiogenesis and reduces myocardial hypoxia. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, S83-S84.	1.6	0
25	Angiogenesis in Adipose Tissue. <i>Methods in Molecular Biology</i> , 2008, 456, 65-81.	0.9	29
26	Suppression of Prostate Cancer Nodal and Systemic Metastasis by Blockade of the Lymphangiogenic Axis. <i>Cancer Research</i> , 2008, 68, 7828-7837.	0.9	148
27	Substrate Matters. <i>Circulation Research</i> , 2007, 101, 536-538.	4.5	14
28	Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collateralogenesis and cardiac function in pigs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12140-12145.	7.1	103
29	Modulating metastasis by a lymphangiogenic switch in prostate cancer. <i>International Journal of Cancer</i> , 2007, 121, 2153-2161.	5.1	52
30	Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. <i>Journal of Clinical Investigation</i> , 2007, 117, 2766-2777.	8.2	254
31	Vascular Endothelial Growth Factor-A Promotes Peritumoral Lymphangiogenesis and Lymphatic Metastasis. <i>Cancer Research</i> , 2005, 65, 9261-9268.	0.9	170
32	Resveratrol as an Angiogenesis Inhibitor. <i>Oxidative Stress and Disease</i> , 2005, , 149-165.	0.3	1
33	Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2476-2481.	7.1	658
34	Angiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice. <i>Circulation Research</i> , 2004, 94, 1579-1588.	4.5	294
35	Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. <i>Nature Medicine</i> , 2003, 9, 604-613.	30.7	677
36	Angiogenesis stimulated by PDGF β CC, a novel member in the PDGF family, involves activation of PDGFR α and β receptors. <i>FASEB Journal</i> , 2002, 16, 1575-1583.	0.5	201

#	ARTICLE	IF	CITATIONS
37	Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8868-8873.	7.1	287
38	Antiangiogenic mechanisms of diet-derived polyphenols. Journal of Nutritional Biochemistry, 2002, 13, 380-390.	4.2	151
39	Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB Journal, 2001, 15, 1798-1800.	0.5	308
40	Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6390-6395.	7.1	404
41	Translocation Properties of Novel Cell Penetrating Transportan and Penetratin Analogues. Bioconjugate Chemistry, 2000, 11, 619-626.	3.6	84
42	Galanin-Based Peptides, Galparan and Transportan, with Receptor-Dependent and Independent Activities. Annals of the New York Academy of Sciences, 1998, 863, 450-453.	3.8	21